Combination therapies for type 1 diabetes: why not now?
von Herrath
Matthias
M
D000818:Animals; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D004195:Disease Models, Animal; D004358:Drug Therapy / Q000379:methods*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016233:Immunotherapy, Active / Q000379:methods*; D010455:Peptides / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007155:Immunologic Factors; D010455:Peptides; D014688:Venoms; D000077270:Exenatide